# CP-675,206 In Patients With Advanced Melanoma

> **NCT00086489** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 118 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** CP-675,206
- **DRUG:** CP-675,206

## Key facts

- **NCT ID:** NCT00086489
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** 2007-05
- **Final completion:** 2009-05
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2012-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00086489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00086489, "CP-675,206 In Patients With Advanced Melanoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00086489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*